Sacubitril
Back to searchMolecule Structure
Scientific Name
Sacubitril
Description of the Drug
Sacubitril is a neprilysin inhibitor used in combination with valsartan as an adjunct to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09292
http://www.drugbank.ca/drugs/DB09292
Brand Name(s)
Not Available
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Neprilysin | SINGLE PROTEIN | INHIBITOR | CHEMBL1944 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL2707112 | |
DrugBank | DB09292 | |
PubChem: Thomson Pharma | 26673060 | |
PubChem | 9811834 | |
LINCS | LSM-45643 | |
Nikkaji | J3.050.252C | |
EPA CompTox Dashboard | DTXSID20164370 | |
DrugCentral | 5012 | |
Brenda | 239140 | 160189 |
ChemicalBook | CB62627304 | |
Guide to Pharmacology | 7857 | |
rxnorm | SACUBITRIL | |
ChEBI | 134714 | |
ZINC | ZINC000003792417 |